2025 Vol.43, N°11 - Suppl.136 - Table of contents

LER & CER - Letter to Editor Rheumatology Commentaries and Controversies

LER & CER: letter to Editor Rheumatology

CER18225
2025,43,11,Suppl.136
Pg. 0003

Free to view

Questioning the diagnosis of familial Mediterranean fever based solely on MEFV mutation: a critical review of overlapping features with inflammatory bowel disease
M.E. Güveli, H. Güveli
DOI: https://doi.org/10.55563/clinexprheumatol/0x0ssk

CER18494
2025,43,11,Suppl.136
Pg. 0004

Free to view

Sacroiliitis and familial Mediterranean fever: unresolved questions
M.E. Güveli, H. Güveli
DOI: https://doi.org/10.55563/clinexprheumatol/8zi6z2

CER18358
2025,43,11,Suppl.136
Pg. 0005

Free to view

Uncertainties in colchicine response criteria in elderly familial Mediterranean fever
M.E. Güveli, H. Güveli
DOI: https://doi.org/10.55563/clinexprheumatol/am59md

CER18522
2025,43,11,Suppl.136
Pg. 0006

Free to view

Use of mycophenolate mofetil in new-onset systemic lupus erythematosus
H. Ogun, S.N. Esatoglu
DOI: https://doi.org/10.55563/clinexprheumatol/fece6x

CER18450
2025,43,11,Suppl.136
Pg. 0007

Free to view

Comments and perspectives on the TREAT EARLIER study
E. Bilgin
DOI: https://doi.org/10.55563/clinexprheumatol/gian28

CER18988
2025,43,11,Suppl.136
Pg. 0008

Free to view

The risk stage of subclinical inflammation is not comparable to the stage of clinical arthritis. Response to ‘Comments and perspectives on the TREAT EARLIER study’
Q.A. Dumoulin, A.H. Van der helm-Van mil
DOI: https://doi.org/10.55563/clinexprheumatol/7454k1

CER18362
2025,43,11,Suppl.136
Pg. 0009

Free to view

Safety of mycophenolate mofetil in Behçet's syndrome: a single centre retrospective study
D. Kerim, F. Tastekin, S. Koroglu, G. Keser, Y. Kabasakal, K. Aksu
DOI: https://doi.org/10.55563/clinexprheumatol/samn0p

CER18512
2025,43,11,Suppl.136
Pg. 0010-0011

Free to view

First report on the safety of the influenza vaccine in patients with paediatric inflammatory rheumatic diseases on JAK inhibitors
D.N. Maritsi, L. Mentesidou, A. Syggelou, M.N. Tsolia
DOI: https://doi.org/10.55563/clinexprheumatol/hlidn3

CER18688
2025,43,11,Suppl.136
Pg. 0012-0013

Free to view

Isolated positivity for anti-ribosomal P antibodies and its utility in clinical practice: a literature review and description of 16 cases
T. Blázquez-Sánchez, M.B. Just-Balerdi, K. Guzmán-López, A. Torres-Roselló, E. Heras-Recuero, A. García-Fernández, F. Rengifo-García, C. Caraballo-Salazar, M.J. Martínez-Becerra, M.C. Vegas-Sánchez, M.Á. González-Gay
DOI: https://doi.org/10.55563/clinexprheumatol/b5v910

CER18806
2025,43,11,Suppl.136
Pg. 0014

Free to view

Exploring the ‘risk’: Comments on the FAERS data regarding the safety of JAK inhibitors by Mikaeili et al.
E. Bilgin
DOI: https://doi.org/10.55563/clinexprheumatol/9m9nbq

CER18775
2025,43,11,Suppl.136
Pg. 0015

Free to view

Beyond the ratios: what influences neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in paediatric systemic lupus erythematosus?
F. Demircioğlu
DOI: https://doi.org/10.55563/clinexprheumatol/k79lo4

CER19049
2025,43,11,Suppl.136
Pg. 0016

Free to view

Use of upadacitinib in giant cell arteritis
H. Ogun, Y. Ozguler
DOI: https://doi.org/10.55563/clinexprheumatol/5ozvlt

CER19239
2025,43,11,Suppl.136
Pg. 0017

Free to view

Reply to: Use of upadacitinib in giant cell arteritis
D. Blockmans, W. Zhao, A.R. Setty, P.A. Merkel
DOI: https://doi.org/10.55563/clinexprheumatol/ozaczo

CER18668
2025,43,11,Suppl.136
Pg. 0018-0019

Free to view

Should multisystem inflammatory syndrome in children be considered occult macrophage activation syndrome?
J.W. Rhim, S.-Y. Lee
DOI: https://doi.org/10.55563/clinexprheumatol/hc0ukd

CER18934
2025,43,11,Suppl.136
Pg. 0020

Free to view

Comment on: Evaluation of the nocebo effect after switching from etanercept or adalimumab originator to a biosimilar: a retrospective study of patients with inflammatory rheumatism
V. Torrente-Segarra, C. Rojas, M. Bonet
DOI: https://doi.org/10.55563/clinexprheumatol/v0g0cd

CER19191
2025,43,11,Suppl.136
Pg. 0021-0022

Free to view

Mevalonate kinase deficiency diagnosed in late adolescence presenting with macrophage activation syndrome
S. Batıbay, T. Bozkurt, E. Dinçses Nas, S. Cilli Hayiroğlu, E. Kasapoğlu
DOI: https://doi.org/10.55563/clinexprheumatol/s5eeqm

CER19476
2025,43,11,Suppl.136
Pg. 0023

Free to view

Comment on: Monocyte-to-HDL ratio as an inflammatory marker: does it reflect blood pressure patterns?
S.O. Çağlar, S. Hira, H. Çağlar
DOI: https://doi.org/10.55563/clinexprheumatol/95ddvp